Articles
Research, news, and myth-busting on peptides, SARMs, and the compounds our community actually searches for.
Semaglutide's Trial Data Is Genuinely Remarkable — And the Legal Ground Just Shifted Under the Research-Labeled Version
SELECT showed semaglutide cut cardiovascular death, heart attack, or stroke by 20% in a 17,604-person trial. Real, landmark data — but since February 2025 the FDA pulled the legal cover compounders were using to sell it, and Novo Nordisk has filed 14 lawsuits in a single week to enforce that.
"Best Peptides for Women" Lists Are Everywhere — Here's One With Nothing to Sell You
Midi, Allara, and SeekPeptides all publish a version of this list, and all of them prescribe or sell something. Here's the same territory, organized by what you're actually trying to solve, with the evidence gaps left in.
PT-141 Has FDA Approval for This — What the Research-Grade Version Actually Costs
Bremelanotide is the rare compound on this blog with real FDA approval for a female-specific indication. Here's what's actually approved, what's sold differently as "PT-141," and the real 119% price spread between suppliers.
Menopause Joint Pain Isn't Arthritis — Here's What's Actually Happening
Estrogen receptors sit directly in your cartilage and joint tissue. When estrogen drops, so does its protection — here's the real mechanism, and where BPC-157/TB-500 claims do and don't hold up.
Brain Fog at 45 Isn't You Losing It — It's Your Estrogen
Estrogen receptors are dense in the brain regions handling memory and focus. Here's the actual mechanism, and why Selank's real clinical evidence doesn't quite address it the way you'd think.
Does Peptide Timing Around Your Cycle Actually Matter?
GH secretagogues, kisspeptin, TB-500 — peptide-user communities have theories about dosing by cycle phase. Here's which ones have any research anchor and which are mechanism-only.
Postpartum Hormone Depletion: The Hair Loss and Fatigue Timeline Nobody Explains
Postpartum hair shedding peaks at month 4-6 and has a real hormonal trigger, not a mystery cause. Here's the actual timeline, what to rule out first, and what the peptide claims do and don't have behind them.
"Mom Pooch" Isn't Fat — What Diastasis Recti Actually Is (and What the Peptide Claims Get Wrong)
Two out of three postpartum women have it, and it has nothing to do with diet. Peptide marketing has quietly attached itself to this one — here's what's actually proven and what isn't.
Does Cycle Syncing Actually Work? What the Evidence Does (and Doesn't) Show
The hormonal swings behind cycle syncing are real. The specific what-to-eat-each-week protocol isn't validated — a board-certified reproductive endocrinologist says the research on cycle syncing itself basically doesn't exist yet.
The Peptide Risks That Hit Women Differently — What Two Academic Researchers Actually Found
Women have a 1.5-2x higher adverse drug reaction rate than men. Two Lancaster University researchers laid out specific, sex-relevant risks in ipamorelin, CJC-1295, TB-500, and GHK-Cu that most peptide guides don't mention.
PCOS and Inositol: What the Evidence Actually Shows (Not Just "Lose Weight")
Inositol is one of the few PCOS supplements with real clinical-guideline-level evidence behind it — including a 2023 PCOS treatment guideline update and head-to-head data against metformin. Here's what the research actually says.
Why Perimenopause Belly Fat Isn't a Diet Failure — and What the GLP-1 Data Actually Shows
Roughly two-thirds of women 40-65 report real abdominal-fat increase during the menopause transition, often starting in the mid-30s. Here's the actual physiology, and what's FDA-approved vs. still investigational in the GLP-1/GIP compounds people ask about most.
Retatrutide Prices in 2026: What It Actually Costs (and Why One Supplier Is 55% Cheaper)
Retatrutide 20mg ranges from £99.99 to £155 across the suppliers we track — a real 55% spread for the identical dose. Here's the actual current pricing across every size, plus what the TRIUMPH-1 data everyone's citing actually says.
How to Read a Dosing Section Without Assuming More Than the Data Supports
Most "standard doses" circulating in this space trace back to a forum post, not a trial. Here's how to tell an FDA-approved dose from a repurposed IV trial number from an untested community convention.
How to Actually Read a "Side Effects" Section
"No adverse events reported" from a 3-person pilot and from a 3,000-person trial look identical as a bullet point. They aren't the same claim — here's how to tell the difference across the compounds we track.
How to Reconstitute Peptides: The Math (and Mistakes) That Actually Matter
A 5mg vial mixed with 2mL of water isn't the same as the same vial mixed with 5mL — the mg-to-mL-to-mcg conversion, syringe units, storage, and the small mistakes that quietly throw off every dose after the first.
The Peptide Price Index: We Compared Every Supplier We Track — Some Prices Vary by Over 200%
MOTS-C 10mg costs £28 at one supplier we track and £95 at another — a 233% spread for what should be the same product. Here's the actual price gap across every compound we compare, snapshot-dated and methodology included.
A COA With No Batch Number Isn't a COA — It's a Screenshot
Half the "lab-tested" badges in this space point to one PDF from one good batch, shown to everyone, forever. Here's the two-second check that tells the difference.
What the FDA's Compounding Review Means for BPC-157
BPC-157 just went in front of the FDA's compounding review board. Here's what Category 2 restriction actually means — and doesn't — for access.
BPC-157's Human Evidence Gap: What the Research Actually Shows
Zero human clinical trials, one small safety pilot, and 35 rat studies: what "100+ studies on BPC-157" really means before you trust the claim.
GHK-Cu Is Trending Fast — Here's What the Actual Science Says
GHK-Cu (copper peptide) searches are up over 1,000% this year. One real human trial backs the hype — here's exactly what it found.
The February Peptide Reclassification Almost No One Covered
HHS quietly moved 14 of 19 restricted peptides further out of reach in February 2026 — the reclassification almost no peptide community covered.
If You Compete in Tested Sport, Know These Peptides Are Banned Outright
BPC-157, TB-500, and CJC-1295 are all WADA-prohibited outright — and a positive drug test isn't even required to trigger a ban.
What the Enhanced Games Actually Proved (and Didn't)
40 athletes competed openly enhanced at the 2026 Enhanced Games in Las Vegas. What the event actually proved about medically-supervised enhancement — and what it didn't.
Retatrutide's Trial Data Is Genuinely Remarkable — Here's the Actual Numbers
45% of patients on Retatrutide's top dose lost 30%+ of body weight in Lilly's own TRIUMPH-1 data. The real numbers, and the one caveat that still matters.
The Retatrutide-Cagrilintide Stack Hype Is Ahead of the Data
Everyone's talking about stacking Retatrutide with Cagrilintide — but no published trial has ever tested that exact combination. Here's the closest real data.
Need something specific, or placing a wholesale order? Message us on Telegram — fastest way to reach us.